PF PFE Pfizer Inc. Loading... : Bullish and Bearish Analyst Opinions

Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.

Pfizer competitive intelligence head Christopher Salatto will speak at AlphaSense summit.

Agilent's pharma reshoring orders are arriving sooner than expected, with orders from five top-10 pharma companies already booked, suggesting the 'reshoring' narrative is converting to tangible revenue earlier than anticipated, with instruments and services being fully incremental. — Incremental demand from reshoring could provide a multi-year growth tailwind, especially for instrument sales, ahead of expectations.

Pfizer executives recently made their biggest insider share purchases in years. With Moderna sparking a massive bull run in cancer-related biotech, Pfizer is positioned as a sympathy play with strong insider conviction. Buy PFE as a value/sympathy play catching a bid from the broader biotech/vaccine sector momentum. Pfizer's pipeline may not have an immediate catalyst comparable to Moderna's Phase 3 results.

The author lists a large basket of tickers without any explicit position language.

A user wants to “double down on the PFE position”, and another mentions “Flu is the worst”. Retail sees PFE as a defensive flu/vaccine-season play. Opportunistic long with limited thread-wide support. Not a consensus pick; no earnings catalyst discussed.

The tweet lists large-cap pharma companies with high short interest.

This collaboration with McKesson's SCRI JV will streamline trial operations and potentially accelerate Pfizer's oncology pipeline, deepening their partnership.

The author defends Pfizer and related biotech names against activist pressure from Starboard.

Author posts tickers with prior context opposing Starboard's influence on Pfizer.

Bought 39,231 shares @ $25.46

Bought 37,632 shares @ $25.52

Merck pipeline stronger than Pfizer.

Pfizer raises its 2026 sales forecast midpoint after reporting strong second-quarter demand.

Management raised FY2026 revenue guidance on strong non-COVID performance and maintained EPS guidance, signaling confidence in execution and offsetting COVID revenue shortfalls.

Pfizer reports second-quarter 2026 revenues of 15 billion dollars with adjusted EPS of 77 cents.

Pfizer beats Q2 revenue estimates and raises its 2026 revenue guidance midpoint.

Pfizer beats Q2 revenue estimates, raises its 2026 revenue guidance midpoint.

Pfizer beats earnings and revenue estimates while maintaining its full-year outlook despite.

Pfizer updates its full-year revenue guidance to a range of 60.5 to 62.5 billion dollars.

Pfizer reports earnings tomorrow. Community sentiment is highly negative heading into the print. Shorting the stock aggressively into earnings. An unexpected earnings beat could cause a short squeeze.

Milvexian's AFib trial (versus Eliquis) readout delayed to Q1 2027 due to slower-than-expected event accrual; DMC 'continues to endorse the study.' This is a classic case of ‘patience is a virtue’—the slower event rate partly reflects the comparator (Eliquis) working well, but also hints at potential favorable unblinded dynamics. — A delay here pushes back the competitive threat to Eliquis (and Pfizer) but also the upside optionality for BMS; the DMC endorsement is a positive signal on the primary endpoint (non-inferiority on strokes).

Senator Alan Armstrong disclosed over 700 stock trades filed late, including purchases of Apple.

Pfizer fails to overturn a cancer drug patent cancellation.

JP Morgan cuts its price target on Pfizer shares to 28 dollars from 30 dollars.

No growth, high dividend but avoid.

Sarcastic commentary on activist engagement at PFE; no explicit directional stance or catalyst.

Watch PFE: author criticizes Pfizer's pipeline and says the company should be put out of its.

US House committee sends letters to Pfizer, Eli Lilly.

US House Committee sends letters to Pfizer, Eli Lilly.